ClinicalTrials.gg
CompletedNCT05194046Updated Jan 18, 2022

Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers

A Phase 1 interventional study of JP-1366 20mg 1capsule and Amoxicillin 500Mg Cap in Helicobacter Pylori Associated Gastrointestinal Disease, sponsored by Onconic Therapeutics Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-18.

Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Nov 2020, registered Nov 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

To evaluate the effect of coadministration of amoxicillin and clarithromycin on safety, tolerability and pharmacokinetics of JP-1366 in healthy subjects and the effect of JP-1366 on safety, tolerability and pharmacokinetics of amoxicillin and clarithromycin in healthy subjects

02

Conditions studied

  • Helicobacter Pylori Associated Gastrointestinal Disease
03

In context

Lead sponsor

Onconic Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject who has fully informed about this study and understand completely, decide to participate voluntarily and agree with the written consent approved by the IRB in Bundang Cha hospital before screening test.
  • A healthy volunteer in the age of upper 19 at the time of the screening test.
  • Subject whose was 18.0 or more and 30.0 or less and whose body weight was 50kg or more if in male, and 45kg or more if in female at the same time.

    • Body Mass Index (BMI) = Body weight(kg) / Height(m)2

Exclusion criteria

Exclusion Criteria:

  1. Medical History
  1. The Subject who has diseases with liver, kidney, nervous system, digestive system, respiratory system, and endocrine system, musculoskeletal system or the blood or tumor disease, cardiovascular disease (including orthostatic hypotension), mental disorder or with history of the disease.
  2. The subject who has a history of gastrointestinal disorders (gastrointestinal ulcers, gastritis, gastric ulcer, gastroesophageal reflux disease, Crohn's disease, etc.) or history of gastrointestinal surgery that may affect the safety and PK/PD Evaluation of the product (Except for simple cecal surgery and hernia surgery)
  3. The subject who has a hereditary disorder (galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption etc.).
  1. Allergy drug and drug abuse
  1. The subject with clinically significant hypersensitivity reactions (Except a slight allergic rhinitis which is no need to administration).
  2. The subject with the history of hypersensitivity reactions to the investigational product, the ingredients in investigational product (FCF, Sunset Yellow FCF), Digestive ulcer drugs and other drugs (aspirin, antibiotics, etc.)
  3. The subject who has a history of drug abuse or who has tested positive for an abuse drug in a drug screening test.
  1. Laboratory Test
  1. Vital Sign Measures of resting blood pressure while the subject remained in the sitting position for at least 3 minutes. Systolic > 150 mmHg or \< 90 mmHg, or diastolic > 100 mmHg or \< 50 mmHg.
  2. Screening laboratory test showing any of the following abnormal laboratory results:

    • , AST, Total > 2.0 x
    • e- \< 60 mL/min/1.73m2 (CKD-EPI formula)
    • Positive result for Serological test (, Ab, Ab, Syphilis regain test)
  3. Clinically significant abnormalities
  1. Prohibited medication and therapy
  1. The subject taking drug of enzyme induction or inhibition within one month prior to the first scheduled drug administration.
  2. The subject who has participated in other clinical trials or bioequivalence studied and received and received clinical trial drug or bioequivalence study drug, within 6 months prior to the first scheduled drug administration.
  3. The subject taking any prohibited drug or herbal medicine, OTC drugs or vitamin within 2 weeks prior to the first scheduled drug administration.
  4. The subject who has taken any diet which affect to drug metabolism (Grapefruit juice, Broccoli, Garlic extract etc.) within 3 days prior to the first scheduled drug administration or who cannot be forbidden the ingestion of it.
  1. Donating and Receiving blood
  1. The subject who did a whole blood donation within 2 months prior to the first scheduled drug administration or a component blood donation (pheresis) within one month
  2. The subject who has received blood transfusions within one month prior to the first scheduled drug administration.
  1. Pregnant and
  1. Pregnant and Lactating women
  2. Subjects who do not agree to use medically acceptable methods of contraception during the period study - Use of an intrauterine device - Use of barrier contraception (for men or women) and using spermicidal at the same time - Vasectomy, tubectomy, tubal ligation, hysterectomy
  1. And others
  1. Subjects who are judged unsuitable to participate in the study in the opinion of the investigator
  2. The subject who continue to drink (over 21units/week, 1 unit = 10g of pure alcohol) within 6 months from screening or who cannot abstain from drinking during the clinical trial period from 3days before the first administration date.
  3. The subject whose average smoking amount exceeds 10 cigarettes per day within 6 months.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Sequence A

    T1→Washout period(D6\~14)→ T3→Washout period(D20\~28)→ T2 * T1: JP-1366 1capsule, 2 times per 1 day, repetition administration for 5 days * T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days * T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days

    Drug: JP-1366 20mg 1capsule · Drug: Amoxicillin 500Mg Cap · Drug: Clarithromycin 500Mg Tab

  • Experimental
    Sequence B

    T1 →Washout period(D6\~14)→ T2→Washout period(D20\~28) → T3 * T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days * T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days * T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days

    Drug: JP-1366 20mg 1capsule · Drug: Amoxicillin 500Mg Cap · Drug: Clarithromycin 500Mg Tab

  • Experimental
    Sequence C

    T2 →Washout period(D6\~14)→ T3→Washout period(D20\~28) → T1 * T1: JP-1366 1capsule, 2 times per 1 day, repetition administration for 5 days * T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days * T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days

    Drug: JP-1366 20mg 1capsule · Drug: Amoxicillin 500Mg Cap · Drug: Clarithromycin 500Mg Tab

  • Experimental
    Sequence D

    T2 →Washout period(D6\~14)→ T1→Washout period(D20\~28) → T3 * T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days * T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days * T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days

    Drug: JP-1366 20mg 1capsule · Drug: Amoxicillin 500Mg Cap · Drug: Clarithromycin 500Mg Tab

  • Experimental
    Sequence E

    T3 →Washout period(D6\~14)→ T1→Washout period(D20\~28) → T2 * T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days * T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days * T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days

    Drug: JP-1366 20mg 1capsule · Drug: Amoxicillin 500Mg Cap · Drug: Clarithromycin 500Mg Tab

  • Experimental
    Sequence F

    T3 →Washout period(D6\~14)→ T2→Washout period(D20\~28) → T1 * T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days * T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days * T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days

    Drug: JP-1366 20mg 1capsule · Drug: Amoxicillin 500Mg Cap · Drug: Clarithromycin 500Mg Tab

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax,ss of JP-1366, Amoxicillin, Clarithromycin

    Time frame: The time of steady state (after repetition administration for 5 days)

  2. AUCτ of JP-1366, Amoxicillin, Clarithromycin

    Time frame: The time of steady state (after repetition administration for 5 days)

Secondary outcomes

  1. Tmax of JP-1366, Amoxicillin, Clarithromycin, 14-OH-Clarithromycin

    Time frame: The time of steady state (after repetition administration for 5 days)

  2. t1/2 of JP-1366, Amoxicillin, Clarithromycin, 14-OH-Clarithromycin

    Time frame: The time of steady state (after repetition administration for 5 days)

  3. CLss/F of JP-1366, Amoxicillin, Clarithromycin, 14-OH-Clarithromycin

    Time frame: The time of steady state (after repetition administration for 5 days)

  4. Vdss/F of JP-1366, Amoxicillin, Clarithromycin, 14-OH-Clarithromycin

    Time frame: The time of steady state (after repetition administration for 5 days)

  5. Cmax,ss of 14-OH-Clarithromycin

    Time frame: The time of steady state (after repetition administration for 5 days)

  6. AUCτ of 14-OH-Clarithromycin

    Time frame: The time of steady state (after repetition administration for 5 days)

  7. 14-OH-Clarithromycin/Clarithromycin metabolic ratio

    Time frame: The time of steady state (after repetition administration for 5 days)

Other outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Vital sign, Physical examination, Laboratory test, 12-lead ECG, Prior/ Concomitant medication, Adverse event.

    Time frame: Through study completion, an average of 46 days

07

Study locations

1 site
  • Cha University Bundang Medical Center
    Gyeonggi-do, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Jan 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2021
First posted
Jan 18, 2022
StartActual
Nov 18, 2020
Primary completionActual
Jan 16, 2021
CompletionActual
Jan 19, 2021
Last update
Jan 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05194046
Responsible party
Sponsor
First posted
Jan 18, 2022
Start date
Nov 18, 2020
Primary completion
Jan 16, 2021
Completion
Jan 19, 2021
Last update
Jan 18, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zastaprazan

Start the discussion